NTRA Natera, Inc.
$328.93▲ +0.86%
Healthcare
Other
After hours
$328.93▲ +0.00%
Sep 11, 7:30 PM ET
Volume 798.0K
Avg Volume (10D) 961.7K
Key Metrics & Fundamentals
Market Cap
$47.41B
P/E Ratio
–
Div Yield
–%
52W Range
157.43 - 343.18
% vs 50 MA
10.82%
% vs 200 MA
38.35%
RSI-14
60.1
MACD Histogram
-2.3200
Beta (1Y vs SPY)
1.27
Free Cash Flow
-$8.64M
Gross Rev
$752.75M
Gross Profit
$485.19M
EBITDA
-$45.15M
COGS
$267.56M
Operating Exp
$560.98M
Operating Income
-$75.79M
EBIT
-$75.79M
Pretax Income
-$67.23M
Net Income
-$66.97M
EPS (Diluted)
-0.47
Price & Volume History
Loading chart…
Recent News
When To Sell Stocks: Why Investors May Want To Walk Away From These IBD 50 Stocks
Investor's Business Daily · Sep 11, 2026 12:00 PM
3 Reasons Investors Love Natera (NTRA)
StockStory · Sep 9, 2026 7:06 PM
UBS Adjusts Price Target on Natera to $435 From $290, Keeps Buy Rating
MT Newswires · Sep 9, 2026 1:41 PM
Jim Cramer Calls Natera (NTRA) “a Promising Story”
Insider Monkey · Sep 9, 2026 1:33 PM
Rothschild & Co Redburn Initiates Natera at Buy With $385 Price Target
MT Newswires · Sep 8, 2026 10:02 AM
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
Business Wire · Sep 1, 2026 10:00 AM
3 Momentum Stocks to Own for Decades
StockStory · Aug 31, 2026 1:34 PM
Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run?
Motley Fool · Aug 29, 2026 10:12 AM
Natera & Angiex Partner to Evaluate AGX101 Response With Signatera
Zacks · Aug 28, 2026 3:22 PM
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
Business Wire · Aug 28, 2026 3:03 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See NTRA's money flow as a full page
Social Sentiment
Avg +0.70 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.